Premium
Disposition of Famotidine in Renal Insufficiency
Author(s) -
Halstenson Charles E.,
Abraham Paul A.,
Opsahl John A.,
Chremos A. N.,
Keane William F.,
Matzke Gary R.
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb02996.x
Subject(s) - volume of distribution , hemodialysis , medicine , urine , famotidine , creatinine , renal function , urology , disposition , endocrinology , pharmacokinetics , psychology , social psychology
The disposition of famotidine was evaluated in 18 patients; Group 1, mild renal insufficiency, [creatinine clearance (CL CR ): 30–60 mL/min]; Group 2, moderate to severe renal insufficiency (CL CR : 10–30 mL/min); Group 3, end‐stage renal disease requiring maintenance hemodialysis (anuric). Blood and urine samples were obtained over a 72‐hour period. Plasma concentration‐time data demonstrated biexponential decay. The terminal elimination half‐life was prolonged in Group 3 (18.6 ± 5.7 hr) compared with Groups 1 (9.3 ± 2.3 hr) and 2 (9.7 ± 1.7 hr), P < .05. Steady‐state volume of distribution ranged from 0.80 to 1.26 L/kg but did not differ among the groups. Total body clearance (CL P ) and renal clearance were significantly lower in Groups 2 and 3 patients compared with Group 1 patients. Nonrenal clearance was not related to CL CR . The CL P correlated well with CL CR (CL P = 1.59 CL CR + 33.8, r = 0.830, P < .05). These data indicate that dosage adjustment may be necessary in patients who have renal insufficiency.